Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19

Tamara Tanner, Dawn M. Wahezi

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


The rapid spread of SARS-CoV-2 infection globally coupled with the relatively high case-fatality rate has led to immediate need for therapeutic intervention to prevent and treat COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 may be exacerbated by a dysregulated host immune response resulting in significant hyperinflammation and cytokine release. The aim of this review is to describe the basis for the immune dysregulation caused by SARS-CoV-2 infection and to examine current investigations into immunomodulatory therapies aimed at targeting the excessive host immune response.

Original languageEnglish (US)
Pages (from-to)81-87
Number of pages7
JournalPaediatric Respiratory Reviews
StatePublished - Sep 2020


  • Children
  • Immune dysregulation
  • Multi-system inflammatory syndrome [MIS-C]
  • SARS-CoV-2
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19'. Together they form a unique fingerprint.

Cite this